Page last updated: 2024-09-03

lestaurtinib and Thyroid Cancer, Anaplastic

lestaurtinib has been researched along with Thyroid Cancer, Anaplastic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barrett, JW; Boutros, PC; Datti, A; Fung, K; Lacefield, JC; Leong, HS; Lowerison, M; MacNeil, D; Mymryk, JS; Nichols, AC; Pinto, N; Prokopec, SD; Ruicci, KM; Searle, K; Vizeacoumar, F; Yoo, J	1

Other Studies

1 other study(ies) available for lestaurtinib and Thyroid Cancer, Anaplastic

Article	Year
Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models. PloS one, 2018, Volume: 13, Issue:11 Topics: Animals; Antineoplastic Agents; Apoptosis; Carbazoles; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chick Embryo; Dose-Response Relationship, Drug; Furans; Humans; Janus Kinase 2; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Xenograft Model Antitumor Assays	2018

Article

Year

Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models.

PloS one, 2018, Volume: 13, Issue:11

Topics: Animals; Antineoplastic Agents; Apoptosis; Carbazoles; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chick Embryo; Dose-Response Relationship, Drug; Furans; Humans; Janus Kinase 2; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Xenograft Model Antitumor Assays

2018